New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 16, 2013
09:22 EDTSTJSt. Jude Medical warning letter not clearing event, says Citigroup
Citigroup believes the next FDA action regarding St. Jude Medical's Sylmar is likely to be a threat of injunction that normally leads to a consent decree. Further, Citi believes the FDA will ultimately have to make a determination on the safety of Durata, with the firm still believing a recall is likely. Citi says the FDA's Sylmar Warning Letter is not a clearing event, but the next step in a process that looks ominous for St. Jude. The firm keeps a Sell rating on the stock with a $32 price target.
News For STJ From The Last 14 Days
Check below for free stories on STJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2014
17:42 EDTSTJJ&J begins sales process for its medical device unit Cordis, WSJ says
Subscribe for More Information
August 26, 2014
16:29 EDTSTJSt. Jude Medical resolves FDA warning letter for Plano facility
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use